The tumble of once highflying tech stocks signals a potential shift in investors chasing eye-popping growth, the New York Times reports.» Read More
Take a look at some of Monday morning's early movers:
Considering Illumina just adopted a poison pill defense strategy, you might think a deal with Roche is out of the question. But Karen Finerman says it's not.
Karen Finerman, Metropolitan Capital Advisors, and Fast Money trader, provides insight on what's next for Illumina, on the heels its recent rejection of Roche's offer.
Roche is willing to spend $5.7 billion on what could be a hostile takeover of Illumina to get into the gene-sequencing market, CEO Severin Schwan told CNBC Friday.
Insight on the value that will be created by a transaction with Illumina, with Severin Schwan, Roche CEO, who discusses Roche's offer for Illumina.
Following are moves you might have missed. Find out why shares of D.R. Horton and Honeywell popped while Illumina and Altria dropped.
CNBC's Kayla Tausche has the details on the Roche tender offer that may be filed today.
Amgen and Celgene, looking to boost oncology offerings, announced separate deals for small biotech companies Thursday, the latest in what analysts expect to be a major wave of biotech mergers.
Stocks ended near session highs Wednesday, reversing their early declines, as the market cheered news that the Fed will not raise interest rates until at least 2014 in addition to maintaining its highly accommodative stance to support the recovery.
Cramer ticks off the many winning trades today.
Illumina landed squarely on Karen Finerman’s trader radar Wednesday with the company in the cross hairs of a hostile bid from Roche.
Keith Moore, MKM Partners, discusses how to play Roche's hostile bid for gene sequencer, Illumin, saying ILMN is likely to fight the takeover. Also an update on SanDisk's earnings, with the Fast Money crew.
Fast Money trader Karen Finerman explains what's behind Roche's tender offer for Illumina; and the best way to play the biotech takeout trend.
U.S. stock index futures struggled for direction Wednesday as investors digested a handful of corporate earnings and ahead of the Federal Reserve's policy statement.
Take a look at some of Wednesday morning's early movers:
Despite a failed attempt at the end of Friday's session to close the week out on a positive note, stocks finished higher on some tepid signs of recovery for the US economy.
The Fast Money traders discuss today's pops and drops. Also, sharing perspective on where the euro is headed, with Willie Williams, Societe General director.
Yes, it's time for "Mad Mail."
Cramer makes the call on viewers' favorite stocks.
Shortly after being named top life sciences analyst, Derik De Bruin dropped by Fast Money with his top picks in the space.